Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010
Date:2/1/2011

the Company's current operating performance and a comparison to the Company's past operating performance.
  • Divestiture-related charges (credits) - These amounts represent (a) fees associated with business divestitures, (b) estimated gains resulting from business divestitures, and (c) gains and related tax impacts that the Company recognized related to the sale of certain non-strategic investments. The fees in the fourth quarter of 2010 represent fees associated with the Company's divestiture of its Neurovascular business and are not representative of on-going operations. The Company completed the sale of its Neurovascular business in January 2011, and the sale of its non-strategic investments during 2009 and the resulting gains are not indicative of future operating performance and are not used by management to assess operating performance. Accordingly, management excluded these amounts for purposes of calculating these non-GAAP measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance.

  • Restructuring and restructuring-related costs - These adjustments represent primarily severance, fixed asset write-offs, costs to transfer production lines from one facility to another, and other costs associated with the Company's 2010 Restructuring plan, Plant Network Optimization program and 2007 Restructuring plan. These expenses are excluded by management in assessing the Company's operating performance, as well as from the Company's operating segments' measures of profit and loss used for making operating decisions and assessing performance. Accordingly, management excluded these charges for purposes of calculating these non-GAAP measures to facilitate an evaluation of the Company's current operating performance and a comparison to the Company's past operating performance.

  • Litigation-related net (credits) charges - These amounts are attributable to certai
    '/>"/>

  • SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

    Related medicine technology :

    1. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System
    2. Boston Scientific Responds to DOJ Civil Lawsuit
    3. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
    4. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
    5. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
    6. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
    7. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
    8. Boston Scientific to Acquire Atritech
    9. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
    10. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
    11. Boston Scientific Completes Acquisition of Sadra Medical
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
    (Date:5/21/2015)... Research and Markets ... of the "Arthroscopy Devices Markets Worldwide" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this report ... market for Arthroscopy Devices. The report discusses ... market for these products. , ,Product - ...
    (Date:5/21/2015)... , 21. Mai 2015 ... ), ein Unternehmen für Arzneimittel im ... Entwicklung und Vermarktung von Locilex® (Pexiganan-Creme ... heute eine wissenschaftliche Posterpräsentation an, welche ... Unternehmens vorstellt, OneStep-1 und OneStep-2, in ...
    Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
    ... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
    ... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
    Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
    (Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
    (Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
    (Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
    (Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
    (Date:5/22/2015)... Carnegie Science Center and ... new partnership to develop BodyTech, a dynamic, three-pronged health ... includes a new exhibit at the Science Center called ... a new traveling science show, Anatomy Adventure, which will ... , Designed to explore a wide range of topics ...
    Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
    ... Provides Update on Oncology Pipeline Progress, SAN DIEGO, ... announced financial results for the three and nine,months ended ... 30,2007, the Company posted revenues of $7.6 million and ... ended September 30, 2007, revenues were $27.1,million and the ...
    ... Human Vaccine Against West Nile Virus Today; ... Disease Endemic in the United States, ... of sanofi-aventis Group, announced today that it has,signed an exclusive ... of a West Nile vaccine to help fight against,this serious, ...
    ... urinary levels of certain molecules might have the potential ... ailment caused by the autoimmune disease lupus, UT Southwestern ... a quartet of molecules may have potential diagnostic significance, ... senior author of a study available online at the ...
    ... CRME TSX: COM, VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ - ... that it will report 2007 third,quarter financial results on ... a teleconference call and webcast at 4:30pm Eastern Time,(1:30pm ... To access the conference call, please dial 416-340-8010 ...
    ... Nov. 12 ,Seeking to expand Indo-U.S. healthcare ... Healthy India launched its inaugural,executive mission to ... from the,most prominent players in healthcare, including: ... Avesthagen, Excel Life Sciences,Cognizant, Stryker, BD, Yes ...
    ... plaguing inner-city youth at epidemic rates, the report of ... Journal of the American College of Surgeons illustrated a ... study showed that Caught in the Crossfire, a hospital-based ... system among youth aged 12 to 20. Additionally, ...
    Cached Medicine News:Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 2Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 3Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 4Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 5Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 6Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 7Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 8Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:Researchers investigate ways to detect lupus-associated kidney disease 2Health News:Cardiome To Release Third Quarter Results 2Health News:Cardiome To Release Third Quarter Results 3Health News:USIBC Launches Healthcare Mission to India 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 3
    Meyerding Laminectomy Retractors, self-retaining....
    Scoville-Haverfield Hemilaminectomy Retractor...
    Bookwalter Spinal Retractor...
    Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
    Medicine Products: